Wyeth’s Torisel To Launch In July Following FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Renal cell carcinoma treatment will compete with Bayer/Onyx’s Nexavar and Pfizer’s Sutent.
You may also be interested in...
Afinitor Wins FDA Nod For Kidney Cancer
The mTor inhibitor targets Sutent or Nexavar treatment failures.
Afinitor Wins FDA Nod For Kidney Cancer
The mTor inhibitor targets Sutent or Nexavar treatment failures.
Good Results Stop Novartis’ Phase III Everolimus Trial
Oral mTOR inhibitor could beat Wyeth’s IV Torisel in kidney cancer, Novartis exec tells “The Pink Sheet” DAILY.